Christopher Newton, MD
Ophthalmology · Providence, RINPI 1952372815
Payments from drug & device makers
What this record shows
15 manufacturers reported payments, led by Rxsight Inc at 46.3% of the total. 2025 is the largest year on record at $1,618, more than ten times the $117 reported in 2019.
Across 87 payments — averaging $39.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$2K
- Alcon$415
- Harrow Eye, LLC$275
- AbbVie$260
- Kala Pharmaceuticals, Inc.$212
- Amgen$159
- plus $511 from 9 others
What the payments were for
- Consulting fees$1,50044%
- Food & beverage$1,90956%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 5 | $1,577 |
| Alcon | 21 | $415 |
| Harrow Eye, LLC | 2 | $275 |
| AbbVie(2 entities) | 15 | $260 |
| Kala Pharmaceuticals, Inc. | 12 | $212 |
| Amgen(2 entities) | 10 | $159 |
| Novartis | 5 | $135 |
| Dompe US, Inc. | 3 | $96 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $85 |
| Bausch & Lomb Americas Inc. | 3 | $61 |
| Sun Pharmaceutical Industries Inc. | 3 | $58 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Biotissue Holdings Inc. | 1 | $18 |
| Rayner Intraocular Lenses Limited | 1 | $15 |
| Lumibird Medical Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,409 in reported general payments places this provider in the 75th percentile of 69 ophthalmology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| InveltysLoteprednol Etabonate | 287 | $82,471 |
| LumiganBimatoprost | 127 | $65,097 |
| RestasisCyclosporine | 51 | $44,297 |
| Bromfenac Sodium | 168 | $31,860 |
| ProlensaBromfenac Sodium | 55 | $18,762 |
| MoxifloxacinMoxifloxacin Hcl | 621 | $17,967 |
| Prednisolone Acetate | 309 | $11,741 |
| Brimonidine Tartrate | 101 | $11,357 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $7,299 |
| Cyclosporine | 12 | $6,563 |
| Travoprost | 31 | $6,073 |
| Latanoprost | 392 | $5,734 |
| Ketorolac Tromethamine | 258 | $5,720 |
| Timolol Maleate | 159 | $5,641 |
| Fluorometholone | 54 | $5,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $260 | $111,685190 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $212 | $82,471287 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $85 | $20,86174 claims |
| AlconSimbrinza | $415 | $4,14719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 69 ophthalmology providers in Rhode Island.
Other ophthalmology in Providence
- Sarah AnisProvidence$163K
- Jesse RichmanProvidence$30K
- Yoash EnzerProvidence$11K
- David TienProvidence$6K
- Jane CookProvidence$4K
- Joseph DucharmeProvidence$3K
- King ToProvidence$2K
- Gaurav GuptaProvidence$2K
- Carolina ChiouProvidence$2K
- Ezra GallerProvidence$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.